{
  "docId": "019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "docSlug": "5bc6ecf6756c39ce2bfe560c6ffb0fc7",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 31,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a map of global disease burden and key product features.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e8f5-748b-98ae-3f4a3c3c68f5/14",
  "deckHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "deckJsonHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5.json",
  "deckAnchorHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.52,
        "y": 0.6
      },
      "kind": "image",
      "text": "Global disease burden map",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bd39391-0231-4a2d-9cbc-d2495189c620",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.48,
        "x": 0.02,
        "y": 0.57
      },
      "kind": "list",
      "text": "VLS-01 Key Product Features: Designed for rapid onset and sustained efficacy; Short duration of psychedelic effect (~30 to 45 minutes)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70fa0494-ec8f-49e9-a1d5-76b9f7073871",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.52,
        "y": 0.27
      },
      "kind": "list",
      "text": "Lead indication overview: Depression is a mood disorder; TRD is diagnosed after two failed courses; FDA approved treatments have slow onset",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a089d58c-a858-4e57-a63f-6b59335d71b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.78,
        "y": 0.6
      },
      "kind": "metric",
      "text": "~300m Global sufferers of depression in 2019",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46ed1ce8-8857-4f9d-a989-a14a17feeb0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.78,
        "y": 0.75
      },
      "kind": "metric",
      "text": "33% Patients who have inadequate response or relapse",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4909b39-c284-4143-8695-353f4160897c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.48,
        "x": 0.02,
        "y": 0.19
      },
      "kind": "table",
      "text": "PRODUCT: DMT in oral transmucosal film; INDICATIONS: Treatment Resistant Depression; IP: Granted U.S. patent; STATUS: Phase 1 data reported 3Q'23",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "559d66cd-f2d6-40a7-ab60-fda8cdcdde73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.02,
        "y": 0.12
      },
      "kind": "title",
      "text": "Designed for a potential rapid, sustained reduction in depressive symptoms from a single dose",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9060bb5-62a2-419c-b70b-4a6295289256",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "Product Overview: VLS-01 for Depression",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33852737-442b-4b3b-8708-b86561ce70df",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "da1b7900-66bf-4e60-b941-9a62685b8f9b",
      "evidence": "The slide contains a 'table/data' component.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 6,
      "beatId": "3567efa9-5c4b-4d3c-88d1-7a53a3a212bc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases the progress and achievements of atai Life Sciences' drug development programs, including efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70da09d2-e8b7-478f-a3d9-ef5654b6b7c9",
      "evidence": "The presentation presents data and results from clinical trials, demonstrating the potential for atai Life Sciences' treatments to become first and best-in-class.",
      "position": 1,
      "objective": "Showcase the potential for first and best-in-class treatments",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}